{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:40:20Z","timestamp":1793763620386,"version":"4.6.1"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Thirteen human malignant neoplasms have been identified as obesity-associated cancers (OACs), ie, the presence of excess body fat is associated with increased risk of developing cancer and worse prognosis in patients with these specific tumors. The glucagon-like peptide receptor agonist (GLP-1RA) class of pharmaceuticals are effective agents for the treatment of type 2 diabetes (T2D) and for achieving weight loss, but the association of GLP-1RAs with the incident risk of 13 OACs is unclear.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the incident risk of each of the 13 OACs in patients with T2D who were prescribed GLP-1RAs vs insulins or metformin.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study was based on a nationwide multicenter database of electronic health records (EHRs) of 113 million US patients. The study population included 1\u202f651\u202f452 patients with T2D who had no prior diagnosis of OACs and were prescribed GLP-1RAs, insulins, or metformin during March 2005 to November 2018. Data analysis was conducted on April 26, 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Prescription of GLP-1RAs, insulins, or metformin.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Incident (first-time) diagnosis of each of the 13 OACs occurring during a 15-year follow-up after the exposure was examined using Cox proportional hazard and Kaplan-Meier survival analyses with censoring applied. Hazard ratios (HRs), cumulative incidences, and 95% CIs were calculated. All models were adjusted for confounders at baseline by propensity-score matching baseline covariates.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In the study population of 1\u202f651\u202f452 patients with T2D (mean [SD] age, 59.8 [15.1] years; 827\u202f873 [50.1%] male and 775\u202f687 [47.0%] female participants; 5780 [0.4%] American Indian or Alaska Native, 65\u202f893 [4.0%] Asian, 281\u202f242 [17.0%] Black, 13\u202f707 [0.8%] Native Hawaiian or Other Pacific Islander, and 1\u202f000\u202f780 [60.6%] White participants), GLP-1RAs compared with insulin were associated with a significant risk reduction in 10 of 13 OACs, including in gallbladder cancer (HR, 0.35; 95% CI, 0.15-0.83), meningioma (HR, 0.37; 95% CI, 0.18-0.74), pancreatic cancer (HR, 0.41; 95% CI, 0.33-0.50), hepatocellular carcinoma (HR, 0.47; 95% CI, 0.36-0.61), ovarian cancer (HR, 0.52; 95% CI, 0.03-0.74), colorectal cancer (HR, 0.54; 95% CI, 0.46-0.64), multiple myeloma (HR, 0.59; 95% CI, 0.44-0.77), esophageal cancer (HR, 0.60; 95% CI, 0.42-0.86), endometrial cancer (HR, 0.74; 95% CI, 0.60-0.91), and kidney cancer (HR, 0.76; 95% CI, 0.64-0.91). Although not statistically significant, the HR for stomach cancer was less than 1 among patients who took GLP-1RAs compared with those who took insulin (HR, 0.73; 95% CI, 0.51-1.03). GLP-1RAs were not associated with a reduced risk of postmenopausal breast cancer or thyroid cancer. Of those cancers that showed a decreased risk among patients taking GLP-1RAs compared with those taking insulin, HRs for patients taking GLP-1RAs vs those taking metformin for colorectal and gallbladder cancer were less than 1, but the risk reduction was not statistically significant. Compared with metformin, GLP-1RAs were not associated with a decreased risk of any cancers, but were associated with an increased risk of kidney cancer (HR, 1.54; 95% CI, 1.27-1.87).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this study, GLP-1RAs were associated with lower risks of specific types of OACs compared with insulins or metformin in patients with T2D. These findings provide preliminary evidence of the potential benefit of GLP-1RAs for cancer prevention in high-risk populations and support further preclinical and clinical studies for the prevention of certain OACs.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.21305","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T11:36:03Z","timestamp":1720179363000},"page":"e2421305","source":"Crossref","is-referenced-by-count":319,"title":["Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes"],"prefix":"10.1001","volume":"7","author":[{"given":"Lindsey","family":"Wang","sequence":"first","affiliation":[{"name":"Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[{"name":"Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio"},{"name":"Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Kaelber","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine, Pediatrics, and Population and Quantitative Health Sciences and the Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan A.","family":"Berger","sequence":"additional","affiliation":[{"name":"Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, Ohio"},{"name":"Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"issue":"8","key":"zoi240679r1","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer\u2014viewpoint of the IARC Working Group.","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi240679r2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00125-022-05854-8","article-title":"Inequalities in cancer mortality trends in people with type 2 diabetes: 20 year population-based study in England.","volume":"66","author":"Ling","year":"2023","journal-title":"Diabetologia"},{"issue":"7","key":"zoi240679r3","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.2337\/db20-0084","article-title":"Is type 2 diabetes causally associated with cancer risk? evidence from a two-sample Mendelian randomization study.","volume":"69","author":"Yuan","year":"2020","journal-title":"Diabetes"},{"issue":"6","key":"zoi240679r4","doi-asserted-by":"publisher","first-page":"R211","DOI":"10.1530\/EJE-19-0566","article-title":"Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes?","volume":"181","author":"Nauck","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"zoi240679r5","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40261-019-00826-0","article-title":"Glucagon-like peptide-1 receptor analogues in type 2 diabetes: their use and differential features.","volume":"39","author":"Lyseng-Williamson","year":"2019","journal-title":"Clin Drug Investig"},{"key":"zoi240679r6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/DMSO.S126763","article-title":"Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists.","volume":"10","author":"Courtney","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"zoi240679r7","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/672658","article-title":"Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.","volume":"2012","author":"Monami","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"zoi240679r8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials.","volume":"11","author":"Gilbert","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"zoi240679r9","doi-asserted-by":"publisher","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.","volume":"344","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"issue":"24","key":"zoi240679r10","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi240679r11","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi240679r12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","article-title":"GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity.","volume":"10","author":"Wang","year":"2024","journal-title":"JAMA Oncol"},{"issue":"2","key":"zoi240679r14","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research.","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"1","key":"zoi240679r15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/wps.20921","article-title":"Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021.","volume":"21","author":"Wang","year":"2022","journal-title":"World Psychiatry"},{"issue":"8","key":"zoi240679r16","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamapediatrics.2022.0945","article-title":"Incidence rates and clinical outcomes of SARS-CoV-2 infection with the Omicron and Delta variants in children younger than 5 years in the US.","volume":"176","author":"Wang","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"7","key":"zoi240679r17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/jama.2022.0210","article-title":"Comparison of mRNA-1273 and BNT162b2 vaccines on breakthrough SARS-CoV-2 infections, hospitalizations, and death during the Delta-predominant period.","volume":"327","author":"Wang","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"zoi240679r18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/alz.12669","article-title":"COVID-19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021.","volume":"19","author":"Wang","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"7","key":"zoi240679r19","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1001\/jamaoncol.2022.1096","article-title":"Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021.","volume":"8","author":"Wang","year":"2022","journal-title":"JAMA Oncol"},{"key":"zoi240679r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100931","article-title":"COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research.","volume":"54","author":"Wang","year":"2022","journal-title":"Blood Rev"},{"issue":"11","key":"zoi240679r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.37575","article-title":"Risks of SARS-CoV-2 breakthrough infection and hospitalization in fully vaccinated patients with multiple myeloma.","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi240679r22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41380-022-01903-1","article-title":"Association of COVID-19 with endocarditis in patients with cocaine or opioid use disorders in the US.","volume":"28","author":"Wang","year":"2023","journal-title":"Mol Psychiatry"},{"issue":"7","key":"zoi240679r23","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1111\/add.16168","article-title":"Repurposing ketamine to treat cocaine use disorder: integration of artificial intelligence-based prediction, expert evaluation, clinical corroboration and mechanism of action analyses.","volume":"118","author":"Gao","year":"2023","journal-title":"Addiction"},{"issue":"2","key":"zoi240679r24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.55496","article-title":"Association of recent SARS-CoV-2 infection with new-onset alcohol use disorder, January 2020 through January 2022.","volume":"6","author":"Olaker","year":"2023","journal-title":"JAMA Netw Open"},{"key":"zoi240679r25","doi-asserted-by":"publisher","DOI":"10.1002\/jclp.23582","author":"Wang","year":"2023","journal-title":"J Clin Psychol"},{"issue":"19","key":"zoi240679r26","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.3390\/cancers14194948","article-title":"Time trend and association of early-onset colorectal cancer with diverticular disease in the United States: 2010-2021.","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"zoi240679r27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort.","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"zoi240679r28","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02498-5","article-title":"Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.","author":"Wang","year":"2024","journal-title":"Mol Psychiatry"},{"issue":"9","key":"zoi240679r30","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1002\/oby.22936","article-title":"Intensive weight loss intervention and cancer risk in adults with type 2 diabetes: analysis of the Look AHEAD randomized clinical trial.","volume":"28","author":"Yeh","year":"2020","journal-title":"Obesity (Silver Spring)"},{"issue":"24","key":"zoi240679r31","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1001\/jama.2022.9009","article-title":"Association of bariatric surgery with cancer risk and mortality in adults with obesity.","volume":"327","author":"Aminian","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"zoi240679r32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50408","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes.","volume":"7","author":"Dankner","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi240679r33","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1210\/en.2011-1864","article-title":"GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.","volume":"153","author":"Madsen","year":"2012","journal-title":"Endocrinology"},{"issue":"18","key":"zoi240679r34","doi-asserted-by":"publisher","first-page":"22232","DOI":"10.18632\/aging.203529","article-title":"High prevalence of thyroid carcinoma in patients with insulin resistance: a meta-analysis of case-control studies.","volume":"13","author":"Zhao","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"17","key":"zoi240679r35","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.3390\/nu15173737","article-title":"Novel treatments for obesity: implications for cancer prevention and treatment.","volume":"15","author":"Cuttica","year":"2023","journal-title":"Nutrients"},{"issue":"5","key":"zoi240679r36","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.2337\/dci23-0016","article-title":"Response to comment on Bezin et al \u201cGLP-1 Receptor Agonists and the Risk of Thyroid Cancer.\u201d Diabetes Care 2023;46:384-390.","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"issue":"2","key":"zoi240679r37","doi-asserted-by":"publisher","first-page":"F443","DOI":"10.1152\/ajprenal.00280.2019","article-title":"Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation.","volume":"318","author":"Hviid","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"zoi240679r38","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1007\/s13277-015-4104-9","article-title":"Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells.","volume":"37","author":"Fidan-Yaylali","year":"2016","journal-title":"Tumour Biol"},{"issue":"3","key":"zoi240679r39","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1210\/clinem\/dgaa891","article-title":"Do GLP-1 receptor agonists increase the risk of breast cancer? a systematic review and meta-analysis.","volume":"106","author":"Piccoli","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"zoi240679r40","first-page":"i5340","article-title":"Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink.","volume":"355","author":"Hicks","year":"2016","journal-title":"BMJ"},{"issue":"5","key":"zoi240679r41","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/1010539513488795","article-title":"Risk factors of breast cancer: a systematic review and meta-analysis.","volume":"25","author":"Anothaisintawee","year":"2013","journal-title":"Asia Pac J Public Health"},{"issue":"2","key":"zoi240679r42","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ijc.23889","article-title":"Breast cancer incidence and mortality in a Caribbean population: comparisons with African-Americans.","volume":"124","author":"Hennis","year":"2009","journal-title":"Int J Cancer"},{"key":"zoi240679r13","unstructured":"TriNetX. September 8, 2021. Accessed May 6, 2023. https:\/\/trinetx.com\/"},{"key":"zoi240679r29","unstructured":"TriNetX. Explore real-world data. August 26, 2021. Accessed January 16, 2024. https:\/\/trinetx.com\/real-world-data\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2820833\/wang_2024_oi_240679_1748628017.61019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T11:00:51Z","timestamp":1749034851000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2820833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.21305","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]}}}